Jenburkt pharmaceuticals Limited has formally disclosed to BSE Limited that it maintains its classification as 'not a large corporate' for the financial year ended March 31, 2026. The disclosure was made on April 14, 2026, in compliance with regulatory requirements.

Regulatory Compliance Disclosure

The company's disclosure was made pursuant to SEBI Circular SEBI/HO/DDHS/CIR/2021/613 dated August 10, 2021, which was subsequently updated on April 13, 2022. This circular establishes criteria for determining whether companies qualify as 'large corporates' under SEBI regulations.

Corporate Status Confirmation

Jenburkt Pharmaceuticals Limited confirmed that it does not meet the applicability criteria mentioned in Clause 2.1 of Chapter XII of the SEBI circular for classification as a large corporate entity. This status determination is significant for regulatory compliance and reporting requirements under SEBI guidelines.

Authorization and Documentation

The disclosure was jointly signed by two key executives of the company. Dilip H. Bhuta, Whole Time Director and CFO, digitally signed the document on April 14, 2026, at 12:46:54 +05'30'. Ashish R. Shah, Sr. Vice President and Company Secretary, also provided his digital signature on the same date at 11:38:52 +05'30'.

The formal communication was addressed to BSE Ltd. at P.J. Towers, Dalal Street, Mumbai - 400 001, requesting the exchange to take the disclosure on record as required by regulatory protocols.

Jenburkt Pharmaceuticals Ltd has filed its quarterly compliance certificate with BSE Ltd, confirming adherence to regulatory requirements for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation as part of its ongoing compliance with SEBI regulations governing depositories and participants.

Regulatory Compliance Certificate

The company filed its certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, on April 7, 2026. The submission was made through a formal communication bearing reference number JPL/CS/2289/2026.

Registrar Confirmation

Bigshare Services Pvt. Ltd., serving as the company's Registrar and Transfer Agent, issued the compliance certificate on April 6, 2026. The registrar confirmed that securities received from depository participants for dematerialization up to March 31, 2026, were properly processed and confirmed to the depositories.

The certificate validates that all security certificates received for dematerialization have been mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories have been substituted in the register of members as registered owners within the stipulated 15-day period of receipt of certificate of securities.

Compliance Framework

The filing demonstrates Jenburkt Pharmaceuticals' commitment to maintaining regulatory compliance with SEBI's framework for depositories and participants. The quarterly certification process ensures transparency in the dematerialization process and proper handling of securities transactions.

The submission was digitally signed by Ashish R. Shah, Vice President & Company Secretary and Compliance Officer, on April 7, 2026, at 12:01:12 +05'30', ensuring the authenticity and timeliness of the regulatory filing.